Thursday, March 11, 2010

Cryolife Deliver Medafor Shareholders No-nonsense Letter

Please Click to Enlarge

Friday, March 5, 2010

Tenaxis Medical Says German Court Nullifies CryoLife 'Kowanko' Patent

The shares of CryoLife, Inc. (CRY: News ) plunged 17.45% in the after-hours trading on Thursday, following the statement by privately held Tenaxis Medical, Inc. regarding the German court nullification of CryoLife 'Kowanko' patent.
Tenaxis Medical noted that the German Federal Patent Court in Munich has indicated their intention to nullify the German Kowanko patent assigned to Kennesaw, Georgia-based CryoLife. The patent is the German part of the European Patent 0 650 512 and is key intellectual property relating to the BioGlue Surgical Adhesive which is marketed worldwide by CryoLife, a processor and distributor of implantable living human tissues for use in cardiac and vascular surgeries.
Ronald Dieck, President and Chief Executive Officer of Tenaxis Medical, said, "We have always believed our intellectual property protection to be strong and we elected to initiate a nullity action in Germany to reinforce our position in this field and maximize the value of our own portfolio. In our review it became clear that the German Kowanko patent was not a valid patent. This assessment will be supported by the upcoming written decision of the Federal Patent Court in Munich, which has indicated that they will nullify the patent."
Dieck added that the company is confident that the Court's decision will lead to the stay of the patent infringement action brought by CryoLife against Tenaxis Medical's product ArterX Vascular Sealant before the Duesseldorf District Court in Germany, pending the outcome of any appeal by CryoLife against the decision of the Federal Patent Court.

Wednesday, March 3, 2010

Cardiva Medical, Inc. Announces Departure of Founder and CEO, Augustine Lien

SUNNYVALE, Calif., March 2 /PRNewswire/ -- Cardiva Medical, Inc. announced today that Founder and CEO Augustine Lien has resigned effective March 5. The company's Board of Directors has appointed Rick Anderson, appointed Chairman of the Board in October 2009, to serve as interim CEO. Mr. Lien will remain a member of the Board of Directors.Mr. Lien founded Cardiva in 2003 and then has led the company for the past 7 years as Chairman and CEO. During that time, Cardiva has launched three highly innovative vascular closure products and grown to over 75 employees. "I owe a sincere thank you to the outstanding employees of Cardiva and to our customers who believe in what we do and embrace our technology," said Lien.Rick Anderson said, "We are appreciative of Augie's leadership and entrepreneurial spirit that has focused on patients and customers. The strength of the company's Catalyst business and our new product development programs are well established, and I am confident the team Augie built will take Cardiva to the next level."Mr. Anderson is Managing Partner at PTV Sciences, a healthcare venture capital and growth equity firm he joined in 2008. Prior to PTV Sciences, Rick was Company Group Chairman, Johnson & Johnson, and Worldwide Franchise Chairman, Cordis Corporation. Mr. Anderson is currently serving as a director on the boards of Cameron Health, InSite Vision (OTC Bulletin Board: INSV), and Tryton Medical, and serves as Chairman of the Board for Cardiva Medical, and IDEV Technologies.

Tuesday, March 2, 2010

Caddisfly larvae spun into surgical tape


SALT LAKE CITY – Often used as fishermen's bait, sticky caddisfly larvae may soon be used to suture wounds, according to researchers at the University of Utah.
The small, moth-like insect spins silk, much like butterflies and spiders, albeit underwater instead of on dry land. The chemical and structural properties of the larvae make it a probable and valuable adhesive tape during surgery because it could be used to hold together skin from the inside.
"I picture it as sort of a wet Band-Aid, maybe used internally in surgery – like using a piece of tape to close an incision, as opposed to sutures," said Russell Stewart, an associate professor of bioengineering at the U. and principal author of a new study of the properties of the fly's silk. The study will be published this week in Biomacromolecules, a journal of the American Chemical Society. He said gluing things together underwater isn't easy.
"Have you ever tried to put a Band-Aid on in the shower? This insect has been doing this for 150 million to 200 million years," he saidStewart studies natural adhesives at the U., including another he discovered made by sandcastle worms on the shore between high tide and low tide ocean waves. That type of natural "glue" has the potential to help repair small broken bones in humans by holding them together. He learned of the potential of the caddisfly larva from a Smithsonian Institution scientist who showed him several of the tube-shaped larval cases that caddisflies spin underwater. It was then that he put on his boots and waded through the Provo River, looking for larvae.
After growing them in his lab, researchers analyzed the silk fibers, finding that they stitched together glass beads from inside their shelters.
"It's like using Scotch tape on the inside of a box to hold it together," Stewart said. "It's really like a tape more than anything else – a tape that works underwater." Next up, they plan to study how strong the silk, or spun larva, can be and whether it can be reproduced synthetically and then used as a surgical adhesive.
In addition to caddisflies, the sandcastle worms, as well as mussels and sea cucumbers, are among the four categories of living organisms that have the ability to make adhesives under water.
And just as it took researchers a while to figure it out, the system of spinning something sticky enough to hold onto its eggs in the aquatic environment evolved independently for the flies, too, helping the creatures live and thrive, Stewart said.

Sunday, February 28, 2010

Medical Hemostat Statistics


I would like to offer you some statistics from this blog as provided by Google Analytics.

As you are aware I currently offer the information at no cost and simply provide a pool of information relating to hemostasis and hemostatic agents/solutions, gathered from a diverse array of sources.

I also encourage discussion (which is not really utilized by many users) in a setting which allows a information and group discussion via a free message board. For readers that have contacted me and had poor response, I apologize I do my very best to respond in a timely manner.

It may also be of interest to see who pay's attention to this information. Please ask for stat's of interest.

My Thanks for your Interest

HG



King Thrombin market yields lower results

THROMBIN-JMI® (thrombin, topical, bovine, USP) net sales totaled $44 million during the fourth quarter and $183 million for the year ended December 31, 2009, compared to $57 million during the fourth quarter and $255 million during the year ended December 31, 2008.

Friday, February 12, 2010

ZymoGenetics, Inc. Q4 2009


On the RECOTHROM front, we continue to gain market share and in January we published pooled safety and immunogenicity data across 8 different clinical studies in the Journal of the American College of Surgeons. This data further supports the safety and differentiation of RECOTHROM as a topical hemostat; we have recently been notified by FDA that they will require more time to analyze the mix of the citizen petition we filed in August which was inline with our expectations for their actions. Less visible but no less important will be the GMP manufacturing of the IL-31 monoclonal antibody and the initiation of IND enabling toxicology studies to support a first half 2011 IND Filing.

The company proceed of $13.6 million profits for the quarter which resulted from a one set of recognition at differed revenue related to restructuring of the their agreement. It was the positive quarter financially was increased RECOTHROM sale further reductions in ongoing operating expenses. A $94 million of cash inflow is from milestone payments.

All of our financial goals for the year ending with the strong cash position strengthen further by the additional $91 million rate of last month. Net sales of RECOTHROM increased $10.6 million for the quarter including 1.4 million (inaudible) to try the clinic launch in Canada. For the year sales of (inaudible) firm within our range of guidance further in asset sales to be included. At the hospital level we continue to see increasing demand in Q4, we estimated the growth that approximately 18% compared to the third quarter. Cognition and license revenue for the quarter were $51.2 million and the largest component of this total was the acceleration of $34 million related to their agreement.

Baxter International Inc. Q4 2009

In our regenerative medicine business we initiated a Phase III study evaluating Tisseel, fiber and sealant as a hemostatic agent in vascular surgery and completed a Phase III study evaluating the use of Artiss fiber and sealant in facial surgery in the United States.......
Sales in regenerative medicine which includes our bio surgery products, totaled $125 million and increased 24%. Sales excluding foreign currency grew 18% and continued to reflect robust growth of Floseal.

JnJ 2009 Earnings Call January 2010

We received FDA approval in October for the SURGIFLO Hemostatic Matrix chip, an advanced flowable hemostat for use in a broad range of surgical procedures. This is our first product launch resulting from Ethicon’s 2008 acquisition of Omrix. The regulatory knowledge gained from this combination product will be valuable as we continue to develop and commercialize other combination products in our pipeline like the Fibrin Pad, which I will address in a minute.......
As I mentioned earlier, Johnson & Johnson leads the industry in developing next-generation advanced hemostats to address the persistent clinical problems associated with bleeding in surgical settings, and we are very excited by the potential of the Fibrin Pad. With our human-plasma based biologics embedded directly into a proprietary matrix, the Fibrin Pad has the potential to uniquely and effectively address bleeding challenges that are hardly unmet by traditional hemostats. As Louise mentioned earlier, the BLI filing for the Fibrin Pad is now expected in the first half of this year.
And obviously, the best thing is to take the $7 billion we are investing and be able to generate products like Simponi or Stelara or Sedasys or the Fibrin Pad. Like, if we see other opportunities to license or to partner, partner may be an even more strategic investment than just a license. But, we will continue to take advantage of each of those in the areas where we see again the biggest opportunities for growth in the corporation.

Monday, January 25, 2010

CryoLife Sends Letter to Medafor, Inc. Shareholders

ATLANTA -- CryoLife, Inc. (NYSE:CRY) , an implantable biological medical device and cardiovascular tissue processing company, announced today that it has sent the following letter toMedafor shareholders discussing its strategic proposal to purchase the outstanding shares of Medafor:

Important Information for Medafor Shareholders
January 21, 2010

Dear Fellow Medafor Shareholder:

You have probably seen the headlines regarding CryoLife's increased stake in Medafor and our proposal to the Medafor board of directors to combine our two companies. I wanted to take this opportunity to personally explain why we have taken this action, why our proposal is financially and strategically compelling, and what you can do to make your opinion heard.

We have great regard for Medafor's MPH® polysaccharide hemostatic technology, and we believe it has significant, untapped growth potential. CryoLife currently has the exclusive right to distribute this technology under the private label HemoStase® within the U.S. for use in cardiac and vascular surgery, and in many international markets for cardiac, vascular, and general surgery, subject to certain exclusions. As Medafor's largest distributor, CryoLife achieved $6 million in sales of HemoStase in 2009.

Unfortunately, we do not believe that Medafor has the resources to maximize the potential of this exciting technology on its own given the capital and other constraints facing the company. At the same time, we believe it is critical that Medafor fully develop this technology in order for Medafor shares to realize their full potential value. We have acquired a large stake in Medafor as a first step in our efforts to combine CryoLife and Medafor, drive additional growth of HemoStase and related products, and deliver earnings and revenue growth for CryoLife and Medafor shareholders.

CryoLife and Medafor: A Strong Strategic Fit

We believe that Medafor's hemostatic technology serves as a perfect complement to CryoLife's product portfolio, particularly our BioGlue® technology. A combination of our companies would allow us to offer surgeons a full range of products to assist them in controlling and preventing bleeding. CryoLife's financial strength (positive cash flow and positive earnings growth), strong direct sales force (45 direct sales representatives in the U.S. and direct sales forces in the United Kingdom and Germany), international distribution network, and experienced management team would allow us to drive additional growth of Medafor beyond its current capabilities, and create greater value for all shareholders.

Combination of CryoLife and Medafor: Our Proposed Offer

On January 13, 2010, we sent a letter to Medafor's board of directors proposing to acquire all of Medafor's remaining outstanding shares for $2.00 per share, to be paid in cash and stock, subject to completion of reasonable due diligence. We believe the price we are offering is full and fair. In fact, it represents a significant premium to that which we understand Medafor's management and board have recently offered to convert debt into equity, and is equivalent to the value at which recent stock transactions have taken place. It is also in line with the valuations of comparable public companies and with recent comparable publicly-disclosed M&A transactions.

While we believe our initial proposal is a strong one, we welcome further dialogue and are open to negotiation with the Medafor board. As we indicated in our recent communication to Medafor, we do not have the most current information regarding Medafor and its prospects, and we are willing to negotiate in good faith to determine Medafor's appropriate value.

Negotiations with the Medafor board would also allow us to determine the right mix of cash and stock. We believe a cash/stock offer is appropriate and attractive, as the cash component would provide Medafor shareholders with immediate and certain value, while the stock portion would allow shareholders to participate in future upside through continued ownership of the combined company. We think the prospects for CryoLife are strong and that Medafor shareholders will be able to realize additional value by owning our stock. It is also important to note that ownership of CryoLife stock would provide you with further liquidity, as you would be able to trade this stock on the New York Stock Exchange. That said, given the current economic climate, we recognize that cash may be more important to some shareholders, and we are therefore prepared to evaluate how to best address this.

Medafor's board has to date refused to enter into negotiations regarding our proposal. Their refusal to enter into discussions with us hurts Medafor shareholders as it impedes your ability to receive a fair price for your shares. The goal of this letter is simply to provide you with more information about our proposal and encourage you to contact Medafor's board to make your voice heard if you have an opinion about Medafor's future and our proposal.

WHAT YOU CAN DO NOW

As Medafor's largest shareholder, we believe that it is important for every shareholder to communicate with the Medafor board. If you have an opinion about anything we've discussed in this letter, please contact your board members today and let them know what you think. The phone numbers and addresses for the Medafor board and management are 877-633-2367 and 2700 Freeway Boulevard, Suite 800, Minneapolis, MN 55430. Make sure your board knows where you stand!

Enclosed with this letter is a copy of CryoLife's 25th anniversary book, which provides information concerning CryoLife, its products and services, and the thousands of people who have been positively impacted by those products and services. If you would like more information about CryoLife and its proposal to acquire Medafor, please visit www.cryolife.com/medaforoffer or contact Nina Devlin at 212-704-8145. Additionally, if you would like to receive any future communications via email, please send an email request to medaforshareholderinfo@cryolife.com.

We are optimistic that you will be as enthusiastic as we are about what CryoLife and Medafor can accomplish together. I look forward to communicating with you again in the near future.


Sincerely,

Steven G. Anderson
Founder, CEO and President